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Abstract
The clinical efficacy and safety of a drug is determined by its activity profile across multiple
proteins in the proteome. However, designing drugs with a specific multi-target profile is both
complex and difficult. Therefore methods to rationally design drugs a priori against profiles of
multiple proteins would have immense value in drug discovery. We describe a new approach for
the automated design of ligands against profiles of multiple drug targets. The method is
demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain
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penetrable ligands with either specific polypharmacology or exquisite selectivity profiles for G-
protein coupled receptors. Overall, 800 ligand-target predictions of prospectively designed ligands
were tested experimentally, of which 75% were confirmed correct. We also demonstrate target
engagement in vivo. The approach can be a useful source of drug leads where multi-target profiles
are required to achieve either selectivity over other drug targets or a desired polypharmacology.
The safety and efficacy of a drug is determined not only by its action on an individual
protein but also by its interactions with multiple proteins in the proteome. The promiscuous
interaction of a drug with undesired proteins frequently causes toxicity1 and adverse
effects2,3. Conversely, the modulation of a single drug target can be therapeutically
insufficient, particularly in complex neuropsychiatric conditions, infectious diseases and
cancer4-6. Instead, it is frequently necessary for a drug to simultaneously engage two or
more targets for therapeutic efficacy7. Psychiatric drugs in particular require multiple
activities against several targets to therapeutically modulate complex neuropsychiatric
domains including perception, cognition and emotion4. However, designing drugs with a
specific multi-target profile – to achieve either exquisite selectivity over other drug targets
or a desired polypharmacology – is a complex and exceedingly difficult task for medicinal
chemistry8. Accordingly, methods are needed to enable drugs to be designed a priori against
several molecular targets simultaneously. Here we describe a solution to the complex
problem of designing ligands against multiple drug target profiles by automated design.
From prediction to design
The problem of designing ligands against a multi-target profile involves the parallel
optimisation of multiple structure-activity relationships (SAR) within a desired range of
physico-chemical properties. The prospect of multi-target drug design has been recently
aided by the development of computational methods that show success in predicting the
molecular targets of drugs3,9-13 (Supplementary Fig. 1) although such approaches are not
intrinsically design methods.
Drug design can be modelled as an evolutionary process of iterative cycles of exploration
and analysis14,15. Adaptive design processes are efficient at solving complex, multi-
objective problems. Accordingly, we developed an automated, adaptive design approach to
optimise ligands against polypharmacological profiles.
Several de novo drug design methods have been proposed previously16-21. However, of
those that have been experimentally tested22-26 only rarely have high affinity ligands been
described and these are all against a single molecular-target objective 24,26. In contrast to
previous de novo approaches we mimicked the creative process by automated learning of
medicinal chemistry design tactics, applying these to the generation of analogues, and then
prioritizing them relative to a set of objectives (Fig. 1a) The development of this approach is
described below, starting from ‘off-target’ predictions, progressing through ligand design
and, finally, the discovery of novel compounds with pre-defined multi-target profiles.
Evolution of a drug
Sir James Black proposed that, “the most fruitful basis for the discovery of a new drug is to
start with an old drug”27. Accordingly, we tested whether the algorithm could automate the
evolution of new biological activities, starting from a known drug. Donepezil (compound 1)
is an acetylcholinesterase inhibitor approved for cognitive enhancement in Alzheimer’s
disease. Bayesian probabilistic activity models9, for 784 molecular targets built from the
ChEMBL database28 predicted a moderate likelihood that donepezil possessed D4 dopamine
receptor activity and a low chance of D2 dopamine receptor activity (Supplementary Table
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1). We found donepezil was a moderately potent D4 inverse agonist (ki=614nM) with
minimal D2 activity (Supplementary Fig. 2 and 3 and Supplementary Tables 2 and 3).
Donepezil’s D4 inverse agonist activity is intriguing given analyses demonstrating a
significant improvement in memory in the Trail Making Test with this drug29 and findings
that D4 antagonists can prevent stress-induced cognitive dysfunction in primates30.
We tested our method by evolving the structure of donepezil with the dual objectives of
improving D2 activity and achieving blood-brain barrier (BBB) penetration. In our approach
the desired multi-objective profile is defined a priori and then expressed as a point in multi-
dimensional space termed ‘the ideal achievement point’. In this first example the objectives
were simply defined as two target properties and, therefore, the space has two dimensions.
Each dimension is defined by a Bayesian score for the predicted activity and a combined
score that describe the absorption, distribution, metabolism and excretion (ADME)
properties suitable for BBB penetration (D2 score=100, ADME score=50). We next
generated alternative chemical structures by a set of structural transformations using
donepezil as the starting structure. The population was subsequently enumerated by
applying a set of transformations to the parent compound(s) of each generation. In contrast
to rules-based or synthetic reaction-based approaches for generating chemical
structures16,31-34, we used a knowledge-based approach by mining the medicinal chemistry
literature28,35. By deriving structural transformations from medicinal chemistry, we
attempted to mimic the creative design process (Supplementary Fig. 4)36. Activity
predictions were calculated for each of the enumerated compounds from all Bayesian
models. Scores representing the likelihood of CNS penetration and good ADME properties
were calculated using the program Stardrop (Optibrium Ltd.) and combined into a single
value. The predicted properties of the enumerated structures were then expressed as points
in multi-dimensional space. The generated structures were subsequently ranked by the
distance (in multi-dimensional space) between the predicted properties for each structure
and the ideal achievement point37 (Fig. 1b). Compounds were filtered for novelty, Lipinski’s
rule-of-five compliance38 and synthetic accessibility39. The top 10,000 prioritized structures
were selected for the next iterative cycle along with 500 random structures from the
remaining population. The process was iterated until either a structure close to the objectives
was discovered or no further improvements were achieved.
Initially, we evolved a series of isoindoles and prioritized them using our achievement
objectives as criteria (Fig. 1c, Supplementary Table 4 and Supplementary Fig. 5). Eight
analogues were then synthesized and tested (Fig. 2, Supplementary Figs. 2 and 6 and
Supplementary Table 5) with all showing significant D2 affinities (ki’s= 156-1,700 nM;
Supplementary Table 3).
The second highest ranking compound (3) – chosen from the final population of evolved
structures – exhibited the highest D2 receptor affinity (ki=156nM). Thus, we successfully
evolved donepezil’s negligible D2 activity into a series of ligands with higher D2 affinities
(Fig. 2). Functionally, 3 was a dual D2 inverse agonist/D4 agonist (Supplementary Fig. 3).
CNS penetration studies showed that 3 penetrates the brain as predicted, with an in vivo
brain/blood ratio (BBR) of 0.5.
Although the evolved compounds were selected for the D2 receptor objective other
predicted activities were not selected against. Accordingly, each of the generated
compounds had a predicted polypharmacology profile. In general, this set of isoindole
analogues was predicted to exhibit promiscuous profiles, with variable activities predicted
for multiple serotonergic, adrenergic and dopaminergic receptor subtypes (Supplementary
Tables 1 and 5). These predicted promiscuous profiles were subsequently confirmed (Fig. 2;
Supplementary Tables 2 and 3), and the predicted multi-target profiles displayed excellent
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agreement with experimentally determined profiles, thereby implying that the approach can
be applied to the de novo design of multi-target agents.
Reducing anti-target activity
The isoindoles exhibited moderately potent affinities for the α1 adrenoceptors (ki’s = 0.9
nM-3,577 nM; mean ki=277 nM; Supplementary Table 3 and Supplementary Fig. 2). Since
α1 adrenoceptor antagonists can induce low blood pressure as a side effect they are
considered ‘anti-targets’ to be avoided in drug design40. A common drug design
optimisation problem is to reduce such anti-target activity whilst maintaining desired on-
target activities. We accordingly evolved the 8 newly-synthesized isoindoles towards a
polypharmacological profile (5-HT1A, D2, D3, D4) with selectivity over the three α1
adrenoreceptors anti-targets (α1A, α1B and α1D) whilst maintaining CNS penetration.
To compare evolutionary strategies, the isoindoles were optimised towards
polypharmacology objectives with and without highly predicted α1 activities filtered-out at
each generation (Fig. 3a, Supplementary Fig. 7, Supplementary Tables 6 and 7). In both
optimisations benzolactams, were ranked the highest (compounds 11a and 10a respectively)
(Fig. 3b and Supplementary Tables 6 and 7). Six benzolactam analogues were then
synthesized based on both sets of objectives (Supplementary Table 8 and Supplementary
Fig. 5). Analogues of the benzo-δ-lactam (3,4,-dihydroisoquinolin-1(2H)-one) (9a, 10a and
11a) and benzo-ε-lactam (2,3,4,5-tetrahydro-1-H-benzo[c]azepin-1-one) (9b, 10b and 11b)
were synthesized for comparison since both ring systems were highly prioritized.
Both predicted and observed receptor activity profiles for the synthesized benzolactams are
shown in Fig. 3b (Supplementary Tables 1 and 3; Supplementary Fig. 2). The 2-pyridine-
piperazine analogues (11a and 11b) have the lowest α1 predictions and, indeed, exhibited
the lowest α1 affinities (mean ki=1,131nM). In agreement with the models, 11a and 11b also
have the lowest affinity for all dopamine D2-like receptors of the benzolactams tested. The
dichloro-phenylpiperazine analogues (9a and 9b) exhibited slighted higher α1 and D2
predictions, which were also confirmed experimentally. In contrast, the 2-methoxy
phenylpiperazine analogues (10a and 10b) exhibited potent affinities against the
polypharmacology profile 5-HT1A, D2, D3 and D4 receptors but also had the highest α1
predictions and were confirmed as the most potent against the α1 receptors (mean
ki=45.3nM) (Fig. 3b). Receptor profiling of the benzolactam series revealed that compared
to the isoindoles, from which the compounds were evolved, the benzolactams achieved the
objective of an increased polypharmacology profile for 5-HT1A,D2, D3 and D4 over the α1
adrenoceptors (Fig. 3b). The benzolactams are 11-fold more selective with respect to D2 and
25-fold more selective with respect to the polypharmacology profile, compared to the
isoindoles. Importantly, the benzolactam 9a penetrated the brain (BBR=5.9), as predicted.
As the benzolactam series was not present in the ChEMBL database (release 1) used to build
the Bayesian models, they constituted a novel chemical series for the system to discover41.
Intriguingly, benzolactam derivatives have recently been independently synthesized and
tested as potent D2/D3 ligands42, however the broader receptor profiles of the compounds
were not evaluated. This observation provides additional confidence that the algorithm is
capable of generating and prioritising novel chemical structures equivalent to those devised
by medicinal chemists.
Potency optimisation
We next explored selectivity in the context of our multi-target objectives and asked whether
we could optimise potent, selective, CNS penetrant D4 receptor ligands starting from the
chemical structure of donepezil. We executed the optimisation in two stages: we optimised
Besnard et al. Page 4













(i) for D4 potency and brain penetrability and (ii) for D4 selectivity. A series of 2-
methylindoline derivatives with high predicted D4 activity was evolved from donepezil after
six generations (Fig. 4a, Supplementary Fig. 9). Notably, compounds belonging to a 2,3-
dihydro-indol-1-yl chemotype were dominant in the prioritized set (Supplementary Table 9).
Compounds 12 and 13, which both belong to the 2,3-dihydro-indol-1-yl class, were then
selected for testing (Supplementary Figs. 5 & 8). The highest ranking compound, 12, was
inactive, while 13, the third highest-ranking design out of the final population, was the most
potent D4 ligand amongst all tested compounds (D4 ki=8.9nM). Via optimisation, 13
represents a 69-fold increase in affinity over donepezil. In contrast to the isoindole and
benzolactams analogues, 13 is predicted to be a highly selective D4 ligand with 95-fold
selectivity over 5-HT2B and weak affinities greater than 1 μM for only 5 other receptors in
our panel of GPCRs (Fig. 2). Importantly, and as predicted, 13 is highly CNS penetrant
(BBR= 7.5).
To verify that the predicted properties of selectivity, potency, and CNS penetration resulted
in D4 receptor activity in vivo, we evaluated 13 on behaviour in wild-type (WT) and D4
receptor knockout (D4R-KO) mice (Fig. 4c-f), as well as in proprotein convertase 7 (PC7)
KO mice (Supplementary Fig. 10a-d) that display a similar D4R-KO phenotype. Although
open field locomotor activity declined in vehicle-treated D4R-WT animals (Fig. 4c), it
remained high and showed little habituation in D4R-KO mice (Supplementary Information).
While 0.7 mg/kg 13 was without significant effect in either genotype, the 1 mg/kg dose
reduced locomotion at 0-20 min in D4R-WT animals. The same dose exerted no effect in
D4R-KO mice. In the centre zone, vehicle-treated D4R-KO mice spent more time in this
area at 21-60 min than D4R-WT controls (Fig. 4d). Centre time in D4R-WT animals was
enhanced at 0-20 min with both doses of 13; in D4R-KO mice it was attenuated at 41-60
min with the 1 mg/kg dose. In the hole-board test, head-poking was increased in vehicle-
treated D4R-KO animals compared to D4R-WT controls (Fig. 4e). In D4R-WT mice 13
augmented head-pokes in a dose-dependent fashion; only the 1 mg/kg dose attenuated head-
poking in mutants. In the zero maze open-area time was increased in vehicle-treated D4R-
KO mice relative to D4R-WT controls (Fig. 4f). One mg/kg compound 13 selectively
increased D4R-WT open-area times to levels of the D4R-KO mice. With regards to PC7
mice, PC7-WT and D4R-WT responses were similar (Supplementary Fig. 8a-d). Although
behaviors in PC7-KO vehicle controls essentially phenocopied those in vehicle-treated D4R-
KO mice, 13 normalized PC7-KO responses to those of PC7-WT controls. By comparison,
D4R-KO mice were largely unresponsive to 13 – demonstrating high D4R selectivity.
Nonetheless, 13 did not appear to be absolutely selective since in D4R-KO animals the 1mg/
kg dose attenuated head-poking in the hole-board test, implying some possible off-target
actions at increased doses.
Automated Invention
Using 13, we further expanded our objective to evolve ligands that (i) were highly selective
for dopamine D4 (ii) were CNS penetrant and (iii) were a novel chemotype. The evolution
of 13 against these objectives resulted in the design of novel morpholino compounds (Fig.
4b, Supplementary Fig. 11) (Supplementary Tables 10 and 11). Compounds with the novel
isoindol-1-yl-ethyl-morpholino backbone were prominent in the prioritised final generation
population of 10,000 structures (ranked 5th, 6th and 9th of the top 10 compounds in
Supplementary Table 10), while most known D4 ligands are 1,4-disubstituted aromatic
piperidines and piperazines (1,4-DAPs). However 1,4-DAPs are rather promiscuous
substructures common in ligands for many biogenic amine GPCRs43. Therefore the
isoindol-1-yl-ethyl-morpholino analogues represent a novel D4 chemotype.
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A library of 24 morpholino analogues (compounds 14-29) was then synthesized and profiled
against our GPCR panel (Supplementary Table 11; Supplementary Fig 5). Individual R and
S morpholino enantiomers were synthesized and assayed separately (chirality designated by
suffix). To further reduce complexity, direct analogues with and without the carbonyl
oxygen were synthesized (e.g. 20 and 21), as this atom was predicted not to be essential to
the overall D4 selectivity profile (Fig. 2).
The assays confirmed the predictions that the new morpholino compounds are generally
highly selective for the D4 receptor over the tested receptors (Fig 2). Seventeen of the
compounds had affinities for the dopamine D4 receptor, ranging from ki=90nM (Compound
27s) to ki=5,526nM (18s) with eight exhibiting affinities less than 1 μM for D4 (compounds
15r, 19s, 21s, 22r, 23s, 26s, 27s and 28s). Compounds containing the ethanone linker-group
were generally less active compared to those with the ethyl linker. For compounds with the
ethyl linker, the S enantiomer was more potent than the R enantiomer. Functional assays of
an exemplar compound (22r) indicated inverse agonism at D4 (Supplementary Figure 3).
In agreement with the design objectives, the morpholinos displayed exquisite selectivity for
the dopamine D4 receptor. Excluding the dopamine receptors, low positive Bayesian scores
were observed for 8 of compounds against 5-HT1A, 16 of the compounds against the 5-
HT2A/B/C receptors, and almost all had very low scores for 5-HT7 serotonin receptors. The
off-target trends were confirmed when the compounds were profiled (Fig. 2). The
morpholino compounds, on average, bound to 3.4 targets (including D4 at ki’s <10μM)
compared to 15.8 targets for the isoindole and benzolactam compounds. Seven of the active
compounds had off-target activities for only 1 of the 20 receptors tested. Compound 26s is
the most selective compound with no measured affinity for any other screened receptor.
Four compounds possessed both relatively high affinity (D4 ki<1μM) and two or fewer off-
target activities out of the 20 GPCRs profiled (21s, 26s, 27s, 28s).
The morpholino series thus represents a new class of highly selective, brain-penetrant, D4-
dopamine receptor ligands. Compounds 27s (D4 ki=90nM; D1 ki=5852nM; BBR=2.0) and
21s (D4 ki=182nM, 5-HT2A ki=3,545nM) qualified as lead compounds that fulfilled all of
our design objectives of novelty, high affinity for the dopamine D4 receptor and exquisite
selectivity and CNS penetration Clearly, the automated design of a novel class of ligands
with a desired multi-target profile demonstrates that the method is able to generate novel,
drug-like lead compounds directly by automated design.
Drug design ex scientia
We focused on the polypharmacology of bioaminergic GPCRs as a convenient test case, due
to the importance of multi-target profiles at these receptors for a variety of neuropsychiatric
indications4. In principle the approach is applicable to all drug target classes limited only by
the requirement for sufficient structure-activity (SAR) data to create useful models9-12. To
generally extend polypharmacology profiling and hence de novo design it will be necessary
to develop inferencing methods to build predictive bioactivity models that integrate all
available SAR, protein structure and protein sequence information together and fuse data
from diverse scoring functions into predictive frameworks44,45.
De novo, automated compound design against multi-target profiles provides a powerful new
approach for discovering new ligands and drug leads and for discovering ligands that satisfy
specific multi-target objectives. The method is particularly useful as a new source of leads
for polypharmacology profiles.
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All machine learning and data mining of the medicinal chemistry structure-activity data
were conducted on the ChEMBL database (release 1) and a pre-release (StARLite version
31)28. The ChEMBL database contains (release 1) over 440,000 compounds abstracted J.
Med Chem. and Bioorg. Med Chem. Letts from 1980 to May 2008. The ChEMBL database
is available for download from the EBI.
Chemical Transformations
A database of chemical transformations was derived from systematically comparing sets of
analogue compounds in ChEMBL28. Sets of analogues with defined structure-activity-
relationships (SAR) were identified in ChEMBL28 usually from individual journal articles.
The transformations database was seeded with a set of common chemical transformation
derived from medicinal chemistry knowledge. The transformations database was then
expanded by identifying novel transformations by systematically applied to each of the
structures associated with each of the journal articles in ChEMBL. All the transformations
were applied to each compound in a journal article. The resulting set of transformed
compounds was compared to the published analogues. Analogues that were not present in
the transformed set highlighted potential transformations that were missing from the
transformation database, and this was subsequently added to the database. This iterative
mining method attempts to regenerate all the reported structures of every medicinal
chemistry publication reported in ChEMBL. The chemical transformations were encoded in
RXN format. The procedure was implemented in Pipeline Pilot. The current database
contains over 700 unique structural transformations.
Bayesian Models
Predictive polypharmacology profiling was undertaken using Bayesian activity models,
based on our previously published approach9. The Bayesian method for polypharmacology
profiling was chosen as it provided both good performance on noisy datasets and a high
speed of calculation51. High confidence models were built using ChEMBL (release 1).
Activity data were filtered to keep only activity endpoint points that had either IC50, ki or
EC50 values and where the ChEMBL confidence score was at least 7 (protein assignment
was direct or homologue). A compound was considered active when the mean activity value
was below 10μM. All inactive compounds were assigned to the target ‘none’. Following this
procedure 133,061 compounds remained with 215,967 activity endpoints, which were used
for model building. Multiple category Laplacian-modified naïve Bayesian models were built
with ECFP6 representations52 for 784 targets. For each model the data were split in two for
the validation step: compounds were clustered and assigned a cluster number. Clusters with
an odd number were assigned to the test set, and the clusters with even number were
assigned to the training set. Models were built with the training set, and the test set was
scored. The training set was scored using its own model as comparison. Finally a model was
built with all data and scored against itself, the training set and whole set should provide
similar validation statistics. Statistics on the performance of the models are described in
Supplementary Table 12. The results for the model containing all 785 targets the results
were very similar to the models for the receptor subsets. Two analyses were used to assess
the performance of the different models. The first analysis provides an overall score and
does not need to specify a cut-off for distinguishing active from inactive compounds. The
area under the Receiver Operating Characteristic (ROC) Curve (AUC) provides an
indication of the ability of the model to prioritize active compounds over inactive
compounds. The ROC curve is the plot of true positive rate versus false positive rate.
However it did not provide information on early enrichment, which was important in studies
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such as the present one where only the top ranking compounds were considered. Therefore
the Boltzmann-Enhanced Discrimination of ROC (BEDROC)53 was used, which solves the
early enrichment issue by adding a weight to compounds recognized early. BEDROC was
derived from the Robust Initial Enhancement (RIE), and the Sum of log of ranks test
(SLR)54 which provided a statistical test to assess which method performs better than
random. The percent of active compound retrieved in the top 5% is also calculated (Recall
=5%). The second analysis required a cut-off to make the distinction between active and
inactive as they varied with the rank of the compounds. For each model, the specificity (true
negative rate), sensitivity (true positive rate), false positive rate, false negative rate,
precision, F-measure and Matthews Correlation Coefficient (MCC) were calculated at
different cut-off values. The cut-off providing the best MCC score was used, as it was
shown to provide better performance55 (Supplementary Fig. 12). The quality of the models
was assessed using an internal leave-one-out validation: one compound was part of the test
set, and was scored using the remaining data as the training set. Then the area under the
ROC curve was calculated (Supplementary Fig. 13). A cut-off score to minimize the sum of
the percent misclassified for category members and for category non-members was
calculated and used to classify compounds in the contingency table.
An All Data Model for dopamine receptors only was built using data from pre release of
ChEMBL (StARLite version 31), with similar numbers of compounds and endpoints. The
model was built without considering the confidence level of target assignment to gather as
much data as possible. This model was used for initial calculation on the evolution of the
isoindole series and the 2,3-dihydro-indol-1-yl series. The quality of the models was
assessed using the same procedures as described above. The results from the All Data
Models and the High Confidence Models were very similar (e.g. D2 model R2=0.998, D4
models R2=0.984).
Profile Prediction Probabilities
The cut-off for a good prediction came from the validation steps for the model. From the test
set, the cut-off value providing the best MCC value was used. For 5-HT1E, a cut-off of zero
was selected. For each ligand-target association, the probability of success was 0.5 (active or
inactive where activity was defined as ki<10μM). To test if the profile predictions were
better than random, an exact binomial test was performed using R (version 2.8.1), and the
cumulative binomial probability was calculated.
Adaptive Optimisation
The adaptive optimization procedure involves defining a set of x achievement objectives
(O1-x), where x is at least one, and an initial parent compound population (PP(G=n) where
n=0 for the initial population) of at least one molecule. All of the members of the parent
population (PP) are subjected to all possible transformations, so as to maximize the pool of
molecules in the transformed population (PT). Each member of the transformed population
is scored and ranked using the achievement objectives (i.e. Bayesian predictions, molecular
properties).
If a stop condition is not satisfied, prioritized individuals with calculated objective
parameters that satisfy the defined thresholds are assigned to an elite population (PE) and
those that fail are assigned to a non-elite population (PN), of which n random members form
a Random Population (PR). For all the calculations performed PE has a maximum size of
10,000 and PR a maximum size of 500. The new parent population (PP(G=n+1)) is created by
merging PE and PR (PP(G=n+1) = PE(G=n) + PR(G=n)). This new population is subjected to
another transformation process. This process is repeated until a stop condition is satisfied.
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The new parent population PP from each generation is also added to a combined pool of all
observed parents (PPall).
The population of transformed compounds from the last iteration and the pooled parent
population are combined and all duplicates and compounds failing structure valency rules
removed to produce a merged population (PM) of unique members (PM= PPall + PT).
Properties and parameters (e.g. Bayesian activity models values, physico-chemical
properties and predicted ADME properties) are calculated for each individual in PM. Each of
the n members of the initial population (PM) is evaluated against the achievement objectives
(O1-x). Multi-objective prioritization is performed by describing the calculated parameters
for a compound of interest as multi-dimensional coordinates. Pareto ranking is a common
method for prioritising multiple criteria17. The Parero frontier maps a surface where all
solutions are considered equivalent (non-dominant) – where an increase in one objective
leads to a decrease in at least one or more other objectives. However finding a Pareto
optimal solution becomes difficult when many objectives are considered56. Instead a vector
scalarisation procedure is employed37.
The results are ranked by the magnitude of the vector ||a|| between the multi-dimensional co-
ordinates of predicted values of the chemical structure of interest (A) and the defined
achievement objective point, (O), with the shortest vector length closest to the ideal in multi-
dimensional space:
(1)
where the achievement objective point has the coordinates (xO1,…,xOn), and predicted
values of the molecule i form the coordinates (xA1,…, xAn). Novelty is assessed by
comparing the generated compound with compounds in ChEMBL, either as an exact match
or by comparison of the Murcko framework41, depending on whether the objectives are
defined in terms of novel compounds or novel chemotypes. Novelty is filtered depending on
the goals.
ADME properties and CNS penetration are calculated using previously publishing Gaussian
Process models57,58 as implemented in StarDrop (Optibrium Ltd). A synthetic accessibility
score, representing historical synthetic knowledge is calculated using a previously published
algorithm39. The synthetic accessibility score combine the observation of fragments in
ChEMBL and a complexity penalty. A limitation of the ECFP6-Bayesian prediction method
is that fingerprints cannot distinguish stereochemistry if the stereochemistry is not encoded
in the training data. In the ChEMBL database only 43% of the chiral compounds with chiral
centres have their stereochemistry fully defined, thus it is not possible to distinguish
between R and S enantiomers. To reduce the complexity of synthesis, compounds with two
or more chiral centres are filtered from the final population.
Receptor Profiling
The detailed experimental protocols for the radioligand and functional receptor assays are
available on the NIMH PDSP website at http://pdsp.med.unc.edu/UNC-CH%20Protocol
%20Book.pdf.
hERG Assay
hERG activity was assayed by the patch clamp method on a PatchXpress platform and by
FluxOR Tl+ assays. Assays were performed as previously described47.
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Metabolic stability was assessed, generating the in vitro intrinsic clearance (Cli) following
incubation of test compound with mouse hepatic microsomes. The assay was performed as
previously described48.
Brain Penetration Measurement
Mice were housed under standard conditions: 12 h light/dark cycle and food and water
available ad libitum throughout the study. The Drug Discovery Unit at the University of
Dundee is dedicated to the humane care, maintenance and use of research animals and
maintains compliance with UK Home Office regulations. All experiments were approved by
the local ethical review committee. The ratio of test compound between brain and blood
(B:B ratio) was assessed following intravenous administration to the female NMRI mouse.
Behavioural Testing
Adult male and female C57BL/6J, D4R-KO mice (Jackson Labs, Bar Harbor, ME), and
PC7-KO mice (D. Comstam, Ecole Polytechnique Fédérale de Lausanne, Lausanne,
Switzerland) were used. PC7 mice were crossed with C57BL/6J mice for more than 10
generations (N.G. Seidah and A. Prat, IRCM, Montreal, QC, Canada). Animals were
maintained in a humidity- and temperature-controlled room under a 14:10 hr light:dark cycle
(lights on 0800 hr). All studies were conducted during the light cycle, between 1000 and
1600 hrs in the following order: zero maze, open field, and hole-board, where tests were
separated by at least by 7 days. Animals were assigned to vehicle- [0.1% DMA with 15% 2-
hydroxypropyl-β-cyclodextrin (Sigma Aldrich, St. Louis, MO)] and compound 13-treated
groups and were maintained in these groups throughout the experiments. Water and
laboratory chow were supplied ad libitum. All experiments were conducted with an
approved protocol from the Duke University Institutional Animal Care and Use Committee
and according to NIH Guide for the Care and Use of Laboratory Animals. To overcome the
high intrinsic clearance in mouse hepatic microsomes of compound 13 (Cli=13.8mL/min/g),
mice were injected (i.p.) with vehicle, or 0.7 or 1 mg/kg compound 13 and placed
immediately into the open field for 60 min as described 49. Activity was monitored as
distance traveled and time spent in the center zone. In the hole-board and zero maze
tests57,50 mice were given (i.p.) vehicle or compound 13 and tested 30 min later. Hole-board
test responses were video-taped for 10 min using high-resolution low-light cameras
(Panasonic NA, Secaucus, NJ) and were scored using the TopScan program (Clever Sys
Inc., Reston, VA) for the rate of head-pokes into the 16 holes. Zero maze behaviors were
video-taped over 5 min and were scored by trained observers blinded to the genotype, sex
and treatment-condition of the animals using the Observer XT10 program (Noldus
Information Technology, Leesburg, VA) for the percent time in the open areas. All
behavioral data are presented as means ±SEM and were analyzed by ANOVA and repeated
measures ANOVA followed by Bonferroni corrected pair-wise comparisons (IBM SPSS 20,
Chicago, IL). A p<0.05 was considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Adaptive drug design
(a) Closed loop of automated ligand design algorithm by multi-objective evolutionary
optimisation. (b) Multi-objective prioritization by vector scalarisation. The multi-target
objectives are defined as the co-ordinates of the ideal achievement point, O, (gold cross) and
the predicted values of each generated compound (coloured circles) are also defined as a co-
ordinates in a multi-dimensional space. The Pareto frontier is displayed as a red dotted line.
The multi-objective prioritisation is inverse to the magnitude of vectors (||a|| < ||b|| < ||c||).
Compound A is prioritised the highest. Compounds C and D have the same vector length (||
c||=||d||) and thus prioritised equally and above the Pareto optimal compounds E and F. (c)
Evolution of donepezil (1) (19% inhibition of D2 receptor @ 10μM; dopamine D2 Bayesian
score = 25) into dopamine D2 inverse agonist 3 (96% inhibition of D2 receptor @ 10μM;
dopamine D2 Bayesian score = 92). The Tanimoto similarity between donepezil and
compound 3 is only 0.35.
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Figure 2. Polypharmacology profiles of designed ligands
Comparison of the predicted Bayesian and observered polypharmacology profiles for (a)
donepezil (1); (b) the isoindole analogues (2-8) – of the 160 ligand-target associations, 100
were correctly predicted by the Bayesian models (p=0.001; probability of success of 0.63
with 95% CI of 0.55 – 0.70); (c) the benzolactam analogues (9a-11b) – of the 160 ligand-
target associations, 107 are correctly predicted (p=1.1e−5); (d) the 2,3-dihydro-indol-1-yl
analogues (12 and 13); (e) and the morpholino analogues (14-29) – of the 540 ligand-target
associations, 437 are correctly predicted (p<2.2e−16). The figure is composed of data in
Supplementary Tables 1 and 3. In total, of the 800 predictions in the matrix, on novel,
prospectively designed ligands, 599 were experimentally confirmed correct (p<2.2e−16),
with a probability of success of 0.75 (95% confidence interval: 0.72 – 0.78).
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Figure 3. Reducing> α1 anti-target activity by evolutionary design
(a) Summary of the evolution of the prioritized benzolactam analogues (compound 11a and
11b) from a parent isoindole analogue (5). The full evolutionary pathway from compound 5
to 11b is show in Supplementary Figure 7. (b) Comparison of polypharmacology profiles
for the Bayesian model score and experimental binding affinities (ki) of compound 5 and
benzolactam analogues (9a-11b) for the seven target objectives (α1A, α1B, α1D vs 5-HT1A,
D2, D3, D4). On average the selectivity ratios for the D2, D3, D4 and 5-HT1A receptors for
the synthesized benzolactams over the α1 receptors are 2.8-, 59-, 58- and 312-fold
respectively. In comparison, the average selectivity ratios for D2, D3, D4 and 5-HT1A for
the isoindole analogues over the α1 receptors are 0.27-, 2.1-, 1- and 14-fold, respectively.
With respect to the algorithm prioritization for the benzolactam analogues (Supplementary
Table 8) against the multi-target objectives, the order of prioritization matches the
experimentally determined order for the analogues (dichloro phenylpiperazine > 2-methoxy
phenylpiperazine >2-pyridine piperazine).
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Figure 4. Evolution of dopamine D4 ligands from donepezil
(a) Summary of the evolution of donepezil (1) (dopamine D4 Bayesian score = 26, D4 ki =
614nM) into dopamine D4 inverse agonist 13 (dopamine D4 Bayesian score = 112, D4 ki =
8.9nM). The Tanimoto similarity between donepezil and compound 13 is only 0.26. The full
evolutionary pathway from donepezil to 13 is show in Supplementary Figure 9 (b) Summary
of the evolution of selective novel dopamine D4 ligands. Compound 13 is further evolvSed
by selection for novelty and D4 selectivity into the morpholino analogues 18, 20 (r and s),
21 (r and s) and 27 (r and s). The full evolutionary pathway from 13 to 27 is show in
Supplementary Figure 11 (c-f) Behavioral analysis of a novel dopamine D4 ligand in D4
receptor (D4R) knockout (KO) mice. (c) Distance travelled in the open field over 60 min by
D4R animals. Mice were given (i.p.) vehicle or 0.7 or 1 mg/kg compound 13 and tested
immediately over 60 min. (d) Time spent in the centre zone in the open field by D4R
animals. (e) The numbers of head-pokes in the hole-board test in D4R mice. Animals were
injected with vehicle or 0.7 or 1 mg/kg compound 13 and were tested 30 min later over 10
min. (f) Percent time in the open areas in the zero maze in D4R (h) mice. Animals were
administered vehicle or compound 13 and tested 30 min later for 5 min. N=8-14 D4R mice/
treatment-condition. *p<0.05, WT versus D4R-KO mice; +p<0.05, comparisons within
genotype to the vehicle; ^p<0.05, comparisons between 0.7 and 1 mg/kg compound 13;
^p<0.05, compared to the 0-20 min time-point.
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